Navigation Links
Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM)
Date:12/4/2008

DUBLIN, December 4 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into a definitive agreement with BioSante Pharmaceuticals, Inc ("BioSante")(Nasdaq: BPAX) to acquire U.S. rights to Elestrin(TM). Elestrin is a fast drying gel formulation of estradiol which is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Elestrin was approved by the U.S. Food and Drug Administration ("FDA") in December 2006 and is patented through June 2022.

Under the terms of the agreement, Azur paid BioSante US$3.3 million comprised of a product licensing fee and payment for the transfer of the trademark and inventories, amongst other items. In addition, Azur Pharma will pay BioSante royalties and contingent milestones based on future net sales of Elestrin.

Azur will market Elestrin to estrogen prescribing physicians in the U.S., comprised mostly of gynecologists, through its women's health and urology sales force. Mr. Seamus Mulligan, Chairman and CEO of Azur, commented, "We are impressed with the potential for Elestrin in the United States given its approved ultra-low dose regimen. The product is an important addition to our women's health product portfolio and we look forward to launching our Elestrin efforts in early 2009."

"We are excited to sign this agreement with Azur," said Mr. Stephen M. Simes, President and CEO of BioSante. "We believe Azur has excellent, established relationships with the leading U.S. gynecological practitioners who write the majority of estrogen prescriptions. Azur is in an excellent position to capture an important share of the U.S. estrogen therapy market, which is currently estimated at approximately US$1.4 billion in annual sales, of which the transdermal segment, mostly patches, is about US$260 million. We look forward
'/>"/>

SOURCE Azur Pharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
2. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
3. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
4. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
5. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
6. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
9. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
10. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
11. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... the Netherlands, February 24 ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader ... the year of 2008. , Highlights, ... delay of the announced, filing date ... - Positive clinical data on GlyberaTM, ...
... SPRINGS, Colo., Feb. 23 The National Academy of ... 2009 finds deficiencies in the nation,s forensic science system ... The report also calls for the development of accreditation ... a code of ethics for experts in all aspects ...
... 23 Texcel Medical, LLC, a full service ... company, has announced the appointment of Barry ... functions at Texcel Medical , which helps ... infrastructure and expertise they need to accelerate the ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2008 2Amsterdam Molecular Therapeutics Reports Full Year Results 2008 3Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations 2Texcel Medical Appoints Barry Smith as President, CEO 2
(Date:7/9/2014)... that can attack soybean crops, why would charcoal rot ... University of Illinois scientists cite the earth,s changing climate ... the fungus that causes charcoal rot. , Fungi may ... Macrophomina phaseolina , the fungus that causes charcoal ... the climate continues to change and we see more ...
(Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
Breaking Biology News(10 mins):Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... with intellectual and developmental disabilities living in family ... routine dental care than those living in institutions, ... associate professor Catherine Binkley, D.D.S., Ph.D. These individuals ... to have poor oral hygiene, increased decay and ...
... shows that following a vegetarian diet and exercising at least ... in African Americans, who are twice as likely to be ... "These findings are encouraging for preventing type 2 diabetes ... disease than other populations," said Serena Tonstad, MD, a professor ...
... called "the trots," "Montezuma,s Revenge," "the runs" and worse. But ... a medicine that could go straight to the offending bacteria ... come true if work by Texas A&M University scientists stays ... Station. A "medicine that grows" is how the phage ...
Cached Biology News:UofL researcher to develop oral health plan for those with IDD 2Vegetarian diet, physical activity protect against diabetes in black population, study shows 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 2Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 3Texas A&M center confronts antibiotic crisis with potential new bacterial treatment 4
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used to ... data obtained from the Experion automated ... in electropherogram and simulated gel views ... calculations in a Results table. This ...
...
Biology Products: